Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Guangzhou Baiyunshan Pharmaceutical Holdings Company ( (HK:0874) ) just unveiled an announcement.
Guangzhou Baiyunshan Pharmaceutical Holdings announced that its subsidiary GP Fund II has formally entered into and activated Partnership Agreement II with GP Capital, Angel Master Fund and Liwan Industrial Investment Fund to establish GP Liwan Fund as part of a previously disclosed connected transaction. The agreement, which took effect on 31 December 2025 with principal terms unchanged from the earlier disclosure, advances the company’s fund investment strategy and may enhance its ability to leverage financial partnerships for future pharmaceutical and related industrial investments, potentially strengthening its capital deployment and strategic positioning in the sector.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
More about Guangzhou Baiyunshan Pharmaceutical Holdings Company
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is a joint stock company with limited liability established in the People’s Republic of China and listed in Hong Kong under H-share stock code 00874. The group operates in the pharmaceutical industry, with its board composed of a mix of executive and independent non-executive directors overseeing its strategy and governance.
Average Trading Volume: 1,271,126
Technical Sentiment Signal: Buy
Current Market Cap: HK$44.2B
See more insights into 0874 stock on TipRanks’ Stock Analysis page.